Crawford, E. David
Heidenreich, Axel
Lawrentschuk, Nathan
Tombal, Bertrand
Pompeo, Antonio C. L.
Mendoza-Valdes, Arturo
Miller, Kurt
Debruyne, Frans M. J.
Klotz, Laurence
Article History
Received: 29 May 2018
Revised: 12 July 2018
Accepted: 20 July 2018
First Online: 21 August 2018
Compliance with ethical standards
:
: E.D.C. has held consulting or advisory roles for Bayer, Mdx, Genomic Health, Janssen, Dendreon, Ferring, and Tolmar, and has received grants from NIH and University of Colorado. A.H. has held consulting or advisory roles for Amgen, Astellas, Ferring, Ipsen, Jansen-Cilag, Pfizer, Sanofi, and Takeda. N.L. has held consulting or advisory roles for A&Z, Astellas, Ipsen, Janssen, and Tolmar. K.M. has held consulting or advisory roles for Amgen, Astellas, Bayer, BMS, Ferring, Janssen, Medivation, Merck, MSD, Novartis, Pfizer, Roche, and Tolmar. L.K. has received grants from Abbvie, Ferring, Sanofi, and Tersera. The remaining authors declare that they have no conflicts of interest. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.